A deep spatial proteomic analysis of healthy fallopian tube epithelium, matching high-grade serous ovarian cancer (HGSOC) ...

High CD8-positive T cell infiltration is linked to shorter PFS in epithelial ovarian cancer patients treated with bevacizumab ...

Bevacizumab addition to chemotherapy showed significant progression-free survival benefits in high-risk epithelial ovarian cancer patients but not in overall survival. The BEV1L study used real-world ...

The impact of homologous recombination deficiency on first-line adjuvant chemotherapy and first-line PARPi maintenance therapy in Chinese patients with epithelial ovarian cancer. This is an ASCO ...

The European Medicines Agency (EMA) has determined that the medicinal product Elahere (mirvetuximab soravtansine, AbbVie Deutschland), indicated for the treatment of adults with folate receptor alpha ...

ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy No more than three prior treatment ...

Recent developments in PARP inhibitor combinations and antibody-drug-conjugates are changing the landscape of ovarian cancer treatment. In spring 2021, Kathy Ventre, 56, of Cincinnati, sensed ...

Ovarian cystic neoplasms are ovarian tumors that have cyst-like qualities. They can include epithelial ovarian tumors and germ cell tumors called teratomas. Ovarian cystic neoplasms can be benign, ...

High-risk MSCs (yellow) are more abundant in fallopian tubes from patients with STIC lesions (bottom) compared to those without these lesions (top). Researchers at the University of Pittsburgh have ...

Recentin plus Lynparza showed some clinical benefits but did not outperform standard chemotherapy in progression-free or overall survival. Side effects such as diarrhea, fatigue, and hypertension were ...